Abeona Therapeutics vs Prelude Therapeutics
Prelude Therapeutics is the larger business, with $12.1m of revenue in fiscal 2025 against $5.8m for Abeona Therapeutics (2.1 times as much). Prelude Therapeutics grew faster (73.4% against 66.3%). Abeona Therapeutics kept more of each dollar of sales as profit: a net margin of 1223.1% against -819.6%. Prelude Therapeutics carries less debt relative to equity (0.0% against 12.6%).
| Latest fiscal year | Abeona TherapeuticsABEO, 2025 | Prelude TherapeuticsPRLD, 2025 |
|---|---|---|
| Revenue | $5.8m | $12.1m |
| Revenue growth | 66.3% | 73.4% |
| Net income | $71.2m | −$99.5m |
| Operating margin | -1536.9% | -861.3% |
| Net margin | 1223.1% | -819.6% |
| Return on equity | 81.8% | -99.5% |
| Free cash flow | −$84.3m | −$56.4m |
| Cash | $78.4m | $35.3m |
| Total debt | $20.0m | $0 |
| Debt to equity | 12.6% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 226 | 79 |
| Market value | $242m | $372m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | — |
| Insider trades, 12 months | 0 buys, 38 sales | 4 buys, 0 sales |